How to buy AVEO Pharmaceuticals stock | $6.62

AVEO Pharmaceuticals Inc is a biotechnology business based in the US. AVEO Pharmaceuticals shares (AVEO) are listed on the NASDAQ and all prices are listed in US Dollars. AVEO Pharmaceuticals employs 49 staff and has a trailing 12-month revenue of around 0.00.

AVEO Pharmaceuticals stock price (NASDAQ: AVEO)

Use our graph to track the performance of AVEO stocks over time.

AVEO Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$6.62
52-week range	$4.95 - $13.21
50-day moving average	$6.48
200-day moving average	$6.42
Wall St. target price	$20.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.95

Buy AVEO Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy AVEO Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVEO Pharmaceuticals price performance over time

Historical closes compared with the close of $6.62 from 2021-10-25

1 week (2021-10-15)	N/A
1 month (2021-09-24)	-0.90%
3 months (2021-07-26)	28.54%
6 months (2021-04-26)	-7.15%

1 year (2020-10-26)	18.43%
2 years (2019-10-25)	621.05%
3 years (2018-10-26)	181.70%
5 years (2016-10-26)	826.26%

AVEO Pharmaceuticals financials

Revenue TTM	$14 million
Gross profit TTM	$-16,660,000
Return on assets TTM	-36.41%
Return on equity TTM	-102.75%
Profit margin	0%
Book value	$1.75
Market capitalisation	$228.9 million

TTM: trailing 12 months

Shorting AVEO Pharmaceuticals shares

There are currently 1.9 million AVEO Pharmaceuticals shares held short by investors – that's known as AVEO Pharmaceuticals's "short interest". This figure is 6% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting AVEO Pharmaceuticals shares can be evaluated.

AVEO Pharmaceuticals's "short interest ratio" (SIR)

AVEO Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AVEO Pharmaceuticals shares currently shorted divided by the average quantity of AVEO Pharmaceuticals shares traded daily (recently around 381591.25248509). AVEO Pharmaceuticals's SIR currently stands at 5.03. In other words for every 100,000 AVEO Pharmaceuticals shares traded daily on the market, roughly 5030 shares are currently held short.

However AVEO Pharmaceuticals's short interest can also be evaluated against the total number of AVEO Pharmaceuticals shares, or, against the total number of tradable AVEO Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVEO Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 AVEO Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0633% of the tradable shares (for every 100,000 tradable AVEO Pharmaceuticals shares, roughly 63 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AVEO Pharmaceuticals.

Find out more about how you can short AVEO Pharmaceuticals stock.

AVEO Pharmaceuticals share dividends

We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months.

Have AVEO Pharmaceuticals's shares ever split?

AVEO Pharmaceuticals's shares were split on a 1:10 basis on 19 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AVEO Pharmaceuticals shares which in turn could have impacted AVEO Pharmaceuticals's share price.

AVEO Pharmaceuticals share price volatility

Over the last 12 months, AVEO Pharmaceuticals's shares have ranged in value from as little as $4.95 up to $13.21. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 1.1926. This would suggest that AVEO Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

AVEO Pharmaceuticals overview

AVEO Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc.

Frequently asked questions

What percentage of AVEO Pharmaceuticals is owned by insiders or institutions?
Currently 0.16% of AVEO Pharmaceuticals shares are held by insiders and 49.932% by institutions. How many people work for AVEO Pharmaceuticals?
Latest data suggests 49 work at AVEO Pharmaceuticals. When does the fiscal year end for AVEO Pharmaceuticals?
AVEO Pharmaceuticals's fiscal year ends in December. Where is AVEO Pharmaceuticals based?
AVEO Pharmaceuticals's address is: 30 Winter Street, Boston, MA, United States, 02108 What is AVEO Pharmaceuticals's ISIN number?
AVEO Pharmaceuticals's international securities identification number is: US0535883070 What is AVEO Pharmaceuticals's CUSIP number?
AVEO Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 053588109